| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pliant Therapeutics Inc. | Bexotegrast (PLN-74809) - (INTEGRIS-PSC) | Primary sclerosing cholangitis (PSC) | Phase 2a | Data Released | Oral | Gastroenterology |
| Pliant Therapeutics Inc. | Bexotegrast (PLN-74809) - (INTEGRIS-IPF) | Idiopathic pulmonary fibrosis (IFP) | Phase 2a | Data Released | Oral | Respiratory |
| Pluri Inc. | NurOwn | Amytrophic lateral sclerosis (ALS) | Phase 3 | IND Clearance | Intrathecal | Neurology |
| Pluri Inc. | NurOwn | Amytrophic lateral sclerosis (ALS) | Phase 3 | IND Clearance | Intrathecal | Neurology |
| Pluri Inc. | PLX-PAD | Muscle injury following hip fracture | Phase 3 | Intramuscular | Orthopedic | |
| Pluri Inc. | PLX-PAD (stem cells) | Critical limb ischemia (CLI) | Phase 3 | Intramuscular | Cardiology | |
| Pluri Inc. | PLX-PAD | COVID-19 / Acute Respiratory Distress Syndrome (ARDS) | Phase 2 | Intramuscular | COVID-19 | |
| Pluri Inc. | PLX-PAD (stem cells) | Intermittent claudication, or IC | Phase 2 | Intramuscular | Cardiology |